Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for NEXIEN BIOPHARMA, INC. (NXEN : OTC)
 
 • Company Description   
Nexien BioPharma Inc. is a pharmaceutical development company. It engages in the formulation, development and commercialization of cannabinoid-based pharmaceuticals. Nexien BioPharma Inc., formerly known as Intiva BioPharma Inc., NY United States.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.06 Daily Weekly Monthly
20 Day Moving Average: 8,134 shares
Shares Outstanding: 60.52 (millions)
Market Capitalization: $3.93 (millions)
Beta: 0.98
52 Week High: $0.20
52 Week Low: $0.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.99% 6.23%
12 Week 32.65% 49.09%
Year To Date -13.33% 5.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4340 E Kentucky Ave. Suite 206
-
Glendale,CO 80246
USA
ph: 303-495-7583
fax: -
None http://www.nexienbiopharma.com
 
 • General Corporate Information   
Officers
Richard Greenberg - Chief Executive Officer
Evan Wasoff - Chief Financial Officer
Robert I. Goldfarb - Chief Operating Officer
Lindy Snider - Director
Courtney Clark - director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 65343D100
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 10/11/22
Share - Related Items
Shares Outstanding: 60.52
Most Recent Split Date: 11.00 (0.17:1)
Beta: 0.98
Market Capitalization: $3.93 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 10/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - 0.70
12/31/21 - 0.65
09/30/21 - 0.16
Quick Ratio
03/31/22 - 0.70
12/31/21 - 0.05
09/30/21 - 0.16
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©